WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory

Pfizer

PfizerAt Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us.

www.pfizer.com

Filters
List of articles in category Pfizer
Title Published Date
Pfizer Wins Viagra Patent Trial 15 August 2011
NCCN Receives $2M Educational Grant from Pfizer 04 August 2011
Pfizer Reports Second-Quarter 2011 Results 02 August 2011
Pfizer To Acquire Icagen 21 July 2011
Pfizer to Explore Strategic Alternatives for its Animal Health and Nutrition Businesses 08 July 2011
Pfizer and ChemRar to Explore Innovative Medical Research and Development Partnership in Russia 01 July 2011
Pfizer Files with the FDA for Review of Axitinib for Patients with Advanced Renal Cell Carcinoma 29 June 2011
Pfizer Conducts First "Virtual" Clinical Trial Allowing Patients to Participate Regardless of Geography 08 June 2011
Pfizer and Hisun Sign MOU to Establish a Joint Venture 03 June 2011
Pfizer Announces New Strategic Partnerships with ICON and PAREXEL International Corporation 27 May 2011
SUTENT® Receives U.S. FDA Approval For Advanced Pancreatic Neuroendocrine Tumors 21 May 2011
Pfizer To Present New Research From Fifteen Compounds 17 May 2011
Pfizer Reports First-Quarter 2011 Results 04 May 2011
Pfizer Announces Top-Line Results of Final Two Pivotal Phase 3 Trials of Tofacitinib (CP-690,550) 29 April 2011
Pfizer Comments on ORAL Sync Tofacitinib Data in EULAR Abstract LB0005 27 April 2011
Pfizer Announces Top-Line Results of Third Phase 3 Clinical Trial of Tofacitinib (CP-690,550) 18 April 2011
Pfizer and Medivation Announce Results from Phase 3 HORIZON Trial of Dimebon in Huntington Disease 12 April 2011
Pfizer to Sell Capsugel to KKR 05 April 2011
Pfizer Posts Details Of Interactions With U.S. Health Care Professionals And Researchers In 2010 01 April 2011
SPIRIVA HandiHaler Prolonged Time To First COPD Exacerbation 23 March 2011
  • Start
  • Prev
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • Next
  • End

Business & Industry

  • Pfizer to acquire Global Blood Therapeutics for $5.4 billion to enhance presence in rare hematology
  • Roche's subcutaneous formulation of Tecentriq demonstrates positive Phase III results
  • Bayer Consumer Health leaders propose new principles for science-led self-care
  • GSK signs agreement to support pandemic preparedness in Europe
  • Pfizer and BioNTech advance COVID-19 vaccine strategy with study start of next-generation vaccine candidate based on enhanced spike protein design

Research & Development

  • New method of nasal vaccine delivery could lead to better vaccines for HIV and COVID-19
  • Research identifies, exploits vulnerability in certain high-risk cancers
  • Scientists create long-acting injectable drug delivery system for tuberculosis
  • Treating cancer by sticking cells in place
  • Vitamin K prevents cell death: a new function for a long-known molecule
  • Disparities in United States COVID-19 vaccine distribution
  • New needle-free nasal vaccine shows promise for COVID-19

Conferences & Events

  • New approach to treatment of deadly kidney cancer
  • SAE Media Group proudly presents the 2nd Annual Aseptic Processing Conference
  • Pharma join together to achieve new standards in digital and patient innovation for clinical transformation
  • SMi's 22nd Annual Pain Therapeutics Conference
  • SMi Group Introduces the 4th Annual Injectable Drug Delivery Conference 2022
  • SMi's 5th Annual Pharmaceutical Microbiology East Coast Conference
  • SMi's 3rd Annual AI in Drug Discovery Conference

Regulatory Affairs

  • FDA approves first systemic treatment for alopecia areata
  • FDA urges drug manufacturers to develop risk management plans to promote a dtronger, resilient drug supply chain
  • FDA limits use of Janssen COVID-19 vaccine to certain individuals
  • EMA establishes Cancer Medicines Forum with academia to optimise cancer treatments in clinical practice
  • FDA approves first generic of Symbicort to treat asthma and COPD
  1. You are here:  
  2. Home
  3. Pfizer
  4. Pfizer to acquire Global Blood Therapeutics for $5.4 billion to enhance presence in rare hematology

About

  • Home
  • Advertise
  • Privacy
  • Cookie Preferences
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2022. All Rights Reserved.